Today we announced positive feedback from the US FDA regarding the registrational study plan for #bexmarilimab in treating (MDS) patients. To read the full press release, visit: otp.tools.investis.com/clients/uk/far… #Faron

Great to see our recent positive FDA feedback regarding #bexmarilimab featured in the Mail Online! Read more here: thisismoney.co.uk/money/investin… #Faron #biotech #drugdevelopment

We are delighted to be featured in LA Weekly, in an article which outlines Faron’s journey so far and our plans for Phase III trials following positive FDA feedback. To read the article, visit: laweekly.com/more-innovativ… #Faron #bexmarilimab #biotech #drugDevelopment

Today we announced the appointment of Dr. Petri Bono as Faron’s new CMO. Dr. Bono’s leading expertise in immunology will be invaluable in supporting Faron's immuno-oncology program and progressing #bexmarilimab to a broader patient population. otp.tools.investis.com/clients/uk/far…

We are thrilled to announce the appointment of Yrjö Wichmann, Faron’s current interim CFO, as our permanent CFO. Press release here: otp.tools.investis.com/clients/uk/far… #Appointment #Faron #Biotech #drugdevelopment #oncology

Pleased to announce we have joined a research consortium that has received a @DeptofDefense Grant to investigate the use of Traumakine in preventing ischemia-reperfusion injury in battlefield victims when using a lifesaving torniquet. otp.tools.investis.com/clients/uk/far…

Our wholly owned #immunotherapy candidate #bexmarilimab has been granted Fast Track Designation by the U.S. FDA for the treatment of relapsed or refractory myelodysplastic syndrome (r/r MDS) in combination with azacitidine bit.ly/3XitBZh #Faron #Biotech #drugDevelopment

Our CEO Dr Juho Jalkanen and CMO Dr Petri Bono are heading to Barcelona later this week for the ESMO - Eur. Oncology Congress 2024. If you’ll be there and would like to connect, do let us know. For more information, visit: esmo.org/meeting-calend… #ESMO #Conference #Faron #Biotech

We are delighted to announce that we have been shortlisted for the ‘Best Oncology R&D Advance’ Award at the Citeline Scrip Awards. Congratulations to all finalists! #Awards #Faron #biotech #drugDevelopment #oncology

Faron will be hosting a hybrid Capital Markets Day on Tuesday, 22 October 2024 at 15:00 pm (EEST). Register to watch the webcast here: faron.videosync.fi/cmd-2024 Read the full press release here: otp.tools.investis.com/clients/uk/far…

Our CEO Dr. MD Juho is attending the @Proactive_UK One2One Biotech Investor Forum this evening in London. To register for the event, visit: proactiveinvestors.co.uk/register/event… #Investors #Faron

Faron hosts its Capital Markets Day today at 08:00am (EDT) / 13:00pm (BST) / 15:00pm (EEST). Learn more in today’s press release bit.ly/3YcaAXX and register to watch the webcast at faron.videosync.fi/cmd-2024 #Faron #biotech #drugdevelopment #oncology

#ICYMI last week we hosted a Capital Markets Day, discussing the strong data continuing to build in our ongoing Phase I/II BEXMAB trial investigating #bexmarilimab in relapsed and refractory myelodysplastic syndrome patients. Watch the full recording: faron.videosync.fi/cmd-2024

Our CEO Juho Jalkanen, CFO Yrjö Wichmann and Business Development Manager Elina Louramo are on the ground in Stockholm this week, attending EBD Group BIO-Europe. Please reach out if you would like to connect with Faron’s team. #BIOEurope #Faron #biotech

Faron has submitted an application for a patent covering the use of soluble Clever-1 or its fragments for inactivating T-cells to treat autoimmune diseases and inflammatory disorders. Read the full press release here: otp.tools.investis.com/clients/uk/far… #Faron #biotech

Today we announced that following interaction with UK Regulatory Authorities, our BEXMAB Study may proceed in the UK, and bexmarilimab has received an Innovation Passport, under the Innovative Licensing and Access Pathway (ILAP) from the MHRA. Read more: otp.tools.investis.com/clients/uk/far…

Faron will be presenting updated clinical data from our BEXMAB trial at the 66th ASH Annual Meeting from 6:00-8:00 pm PST on Monday 9 December at the San Diego Convention Center, Halls G-H.

Our CEO Juho Jalkanen was featured in the Citeline In Vivo Podcast. To listen to the podcast, please visit: insights.citeline.com/in-vivo/podcas… #Podcast #Faron #biotech #drugdevelopment #oncology #heatlhcare

The final patient has been identified for our BEXMAB Phase II dose optimization study in refractory or relapsed myelodysplastic syndrome (r/r MDS), as well as the BEXMAB Phase I/II study in frontline high risk (HR) MDS. Read the full press release here: faron.com/releases-and-p…

Faron publishes its Financial Statement Release and Annual Report for the year ended December 31 2024, next Thursday, February 27. Register for the analyst, investor and media webinar taking place that morning, 9am GMT / 11am EET, at faron.events.inderes.com/q4-2024 #biotech #oncology